scholarly journals Efficacy and safety of AXS‐05, a novel oral NMDA receptor antagonist with multimodal activity in agitation associated with Alzheimer’s disease: Results from ADVANCE‐1 — A phase 2/3, double‐blind, active and placebo‐controlled trial

2020 ◽  
Vol 16 (S6) ◽  
Author(s):  
Cedric O'Gorman ◽  
Amanda Jones ◽  
Jeffrey L. Cummings ◽  
Herriot Tabuteau
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Nmda Receptor ◽  
Receptor Antagonist ◽  
Controlled Trial ◽  
Nmda Receptor Antagonist ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Double Blind

A PHASE 2 MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF EDONERPIC (T-817) IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE

2017 ◽  
Vol 13 (7) ◽  
pp. P1572
Author(s):  
Lon S. Schneider ◽  
Ronald G. Thomas ◽  
Suzanne Hendrix ◽  
James B. Brewer ◽  
Robert A. Rissman ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Trial ◽  
Phase 2 ◽  
Efficacy And Safety

scholarly journals Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer’s disease: A phase 2, double‐blind, randomized, placebo‐controlled trial

2020 ◽  
Vol 16 (S9) ◽  
Author(s):  
Raymond Scott Turner ◽  
Michaeline Hebron ◽  
Abigail Lawler ◽  
Elizabeth Mundel ◽  
Nadia Yusuf ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Trial ◽  
Phase 2 ◽  
Double Blind

The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial

Pain ◽  
1998 ◽  
Vol 75 (2) ◽  
pp. 349-354 ◽  
Author(s):  
Dorit Pud ◽  
Elon Eisenberg ◽  
Ada Spitzer ◽  
Rivka Adler ◽  
Georgetta Fried ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Nmda Receptor ◽  
Receptor Antagonist ◽  
Cancer Patients ◽  
Controlled Trial ◽  
Nmda Receptor Antagonist ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document